Nurullah İlhan,MD· @drnurullahilhan · X·· 8 hours agoScore70
Body
VIKTORIA-1: HR+/HER2−, PIK3CA-mutant advanced breast cancer.
Subgroup update supports prior primary PFS success with gedatolisib + palbociclib + fulvestrant.
Visceral metastases:
PFS 9.8 vs 5.6 months with alpelisib + fulvestrant; HR 0.52.
#VIKTORIA1 #ESMO2026 #BCSM
6 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA16matched by Rapid oral 1: Breast cancer, advanced stage
VIKTORIA-1: Updated results of a randomized, open-label, phase 3 study of gedatolisib (geda) + fulvestrant (fulv) ± palbociclib (palbo) vs standard of care in patients (pts) with HR+/HER2- advanced breast cancer (ABC) (Study 2)
https://esmocongress.esmo.orgSource: Nurullah İlhan,MD · x.com